Colorectal Cancer – Landscape & Forecast – Disease Landscape & Forecast
Chemotherapy remains the cornerstone of colorectal cancer treatment and is prescribed with angiogenesis or EGFR inhibitors in the metastatic setting. The colorectal cancer treatment landscape has shifted toward personalized treatment, with tumor sidedness and various biomarkers playing an important role in treatment selection. The colorectal cancer market is changing, largely fueled by the entry of immune checkpoint inhibitors (Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo) and BRAF inhibitors (Array BioPharma / Pfizer’s Braftovi). Both Opdivo (with or without Yervoy) and Keytruda are approved for advanced or recurrent MSI-H / dMMR colorectal cancer. Keytruda is also approved as first-line treatment for MSI-H / dMMR metastatic colorectal cancer. Braftovi in combination with an EGFR inhibitor (Erbitux) is now available for use as subsequent therapy for metastatic colorectal cancer patients with a BRAF V600E mutation. Given the intense Phase II/III pipeline activity, we anticipate the approval of several new therapies for colorectal cancer during the forecast period, such as the VEGFR inhibitor fruquintinib (Hutchmed) and KRAS inhibitor adagrasib (Mirati Therapeutics). These therapies will contribute to the robust market growth anticipated over the 2021-2031 forecast period.
QUESTIONS ANSWERED
- How large are the drug-treatable colorectal cancer populations? How do patient populations differ by disease stage and key biomarkers, and how will drug-treatment rates change over the 2021-2031 forecast period?
- What are interviewed experts’ views on current and emerging late-phase therapies, and what strategies are companies pursuing to secure uptake and share in the colorectal cancer market?
- Which are the most promising emerging therapies in the late-phase pipeline that are poised to launch for colorectal cancer, and what unmet needs do they address? What uptake and patient shares can late-phase pipeline agents currently in development for colorectal cancer expect to secure?
- What are the key drivers and constraints in the colorectal cancer market, and how will they change in the major markets over the forecast period?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Table of contents
- Colorectal Cancer - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Colorectal cancer u2013 key findings u2013 November 2022
- Key updates
- January 2023
- Q4 2022
- November 2022
- Q3 2022
- September 2022
- Q2 2022
- May 2022
- May 2022
- April 2022
- Q1 2022
- March 2022
- Market outlook
- Key findings
- Market share of drug classes for colorectal cancer: 2021
- Market share of drug classes for colorectal cancer: 2031
- Drug-treatable population share and major-market sales share in colorectal cancer: 2021
- Drug-treatable population share and major-market sales share in colorectal cancer: 2031
- Population positioning of therapies in colorectal cancer
- Colorectal cancer SWOT analysis
- Market drivers and constraints
- What factors are driving the market for colorectal cancer?
- What factors are constraining the market for colorectal cancer?
- Major-market sales of key drug classes for colorectal cancer: 2021-2031
- Major-market sales of key drugs for colorectal cancer by brand / biosimilar: 2021-2031
- Segment-specific trends
- Patient-share dynamics of key players in stage III colon cancer, United States (2021-2031)
- Patient-share dynamics of key players in stage IV first-line, left-sided, BRAF wild-type, RAS wild-type colorectal cancer, United States (2021-2031)
- Patient-share dynamics of key players in stage IV first-line, right-sided, BRAF wild-type, RAS wild-type colorectal cancer, United States (2021-2031)
- Patient-share dynamics of key players in stage IV first-line, BRAF wild-type, RAS-mutant colorectal cancer, United States (2021-2031)
- Patient-share dynamics of key players in stage IV first-line, BRAF-mutant, RAS wild-type colorectal cancer, United States (2021-2031)
- Second-line metastatic colorectal cancer
- Patient-share dynamics of key players in stage IV second-line, left-sided, BRAF wild-type, RAS wild-type colorectal cancer, United States (2021-2031)
- Patient-share dynamics of key players in stage IV second-line, right-sided, BRAF wild-type, RAS wild-type colorectal cancer, United States (2021-2031)
- Patient-share dynamics of key players in stage IV second-line, BRAF wild-type, RAS-mutant colorectal cancer, United States (2021-2031)
- Patient-share dynamics of key players in stage IV second-line, BRAF-mutant, RAS wild-type colorectal cancer, United States (2021-2031)
- Patient-share dynamics of key players in stage IV third-line, left-sided, BRAF wild-type, RAS wild-type colorectal cancer, United States: 2021-2031
- Patient-share dynamics of key players in stage IV third-line, right-sided, BRAF wild-type, RAS wild-type colorectal cancer, United States: 2021-2031
- Patient-share dynamics of key players in stage IV third-line, BRAF wild-type, RAS-mutant colorectal cancer, United States: 2021-2031
- Patient-share dynamics of key players in stage IV third-line, BRAF-mutant, RAS wild-type colorectal cancer, United States: 2021-2031
- Key findings
- Forecast
- Market forecast assumptions
- Market forecast dashboard
- Etiology and pathophysiology
- Disease overview
- Disease pathophysiology
- Etiology
- Risk factors for developing colorectal cancer
- Pathophysiology
- Proposed adenoma-carcinoma sequence model for colorectal cancer with chromosomal instability
- Staging and classification
- Staging of colorectal cancer
- TNM classification of colorectal cancer
- Modified Astler-Coller Dukes staging system vs. AJCC/UICC colorectal cancer (TNM) staging system
- Symptoms according to tumor location in colorectal cancer
- Screening for colorectal cancer
- Prognostic factors in colorectal cancer
- Key pathways and drug targets
- Drug targets for colorectal cancer
- Select genes reportedly involved in colorectal cancer
- Disease overview
- Epidemiology
- Key findings
- Key updates
- Epidemiology populations
- Disease definition
- Methods
- Sources used for diagnosed incidence of colorectal cancer
- Diagnosed incident cases of colorectal cancer: 2021-2031
- Disease definition
- Methods
- Sources used for the stage distribution of colorectal cancer
- Diagnosed incident cases of colorectal cancer by stage distribution: 2021-2031
- Definition
- Methods
- Sources used for recurrent incidence of colorectal cancer
- Recurrent incident cases of colorectal cancer: 2021-2031
- Colorectal cancer patient flow
- Drug-treatable cases of colorectal cancer: 2021-2031
- Drug-treated cases of colorectal cancer: 2021-2031
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for colorectal cancer
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for colorectal cancer
- Current treatments used for colorectal cancer
- Market events impacting the use of key current therapies in colorectal cancer
- Key results from select clinical trials investigating bevacizumab for the treatment of colorectal cancer
- Expert insight: bevacizumab
- Key results from select clinical trials investigating Zaltrap for the treatment of colorectal cancer
- Expert insight: Zaltrap
- Key results from select clinical trials investigating Cyramza for the treatment of colorectal cancer
- Ongoing clinical development of Cyramza
- Key ongoing clinical trials of Cyramza in the treatment of colorectal cancer
- Expert insight: Cyramza
- Key results from select clinical trials investigating Stivarga for the treatment of colorectal cancer
- Expert insight: Stivarga
- Key results from select clinical trials investigating Erbitux for the treatment of colorectal cancer
- Ongoing clinical development of Erbitux
- Key ongoing clinical trials of Erbitux in the treatment of colorectal cancer
- Expert insight: Erbitux
- Key results from select clinical trials investigating Vectibix for the treatment of colorectal cancer
- Ongoing clinical development of Vectibix
- Key ongoing clinical trials of Vectibix in the treatment of colorectal cancer
- Expert insight: Vectibix
- Key results from select clinical trials investigating Keytruda for the treatment of colorectal cancer
- Ongoing clinical development of Keytruda
- Key ongoing clinical trials of Keytruda in the treatment of colorectal cancer
- Key results from select clinical trials investigating Opdivo for the treatment of colorectal cancer
- Ongoing clinical development of Opdivo
- Key ongoing clinical trials of Opdivo in the treatment of colorectal cancer
- Expert insight: Opdivo
- Key results from select clinical trials investigating Braftovi for the treatment of colorectal cancer
- Ongoing clinical development of Braftovi
- Key ongoing clinical trials of Braftovi in the treatment of colorectal cancer
- Expert insight: Braftovi
- Key results from select clinical trials investigating Lonsurf for the treatment of colorectal cancer
- Ongoing clinical development of Lonsurf
- Key ongoing clinical trials of Lonsurf in the treatment of colorectal cancer
- Expert insight: Lonsurf
- Key results from select clinical trials investigating Perjeta and trastuzumab combination therapy for the treatment of colorectal cancer
- Ongoing clinical development of Perjeta and trastuzumab combination therapy
- Key ongoing clinical trials of Perjeta and trastuzumab combination therapy in the treatment of colorectal cancer
- Expert insight: Perjeta plus trastuzumab
- Key results from select clinical trials investigating Tukysa for the treatment of colorectal cancer
- Ongoing clinical development of Tukysa
- Key ongoing clinical trials of Tukysa in the treatment of colorectal cancer
- Expert insight: Tukysa
- Medical practice
- Stage II/III colon cancer
- Stage II/III rectal cancer
- Treatment of colorectal cancer with resectable liver metastases
- Second-line treatment of metastatic colorectal cancer
- Third- and later-line treatment of metastatic colorectal cancer
- Patient characteristics influencing drug selection in colorectal cancer
- Treatment decision tree for stage II/III colon and rectal cancer: G7
- Treatment decision tree for stage IV colorectal cancer: United States
- Treatment decision tree for stage IV colorectal cancer: France, Germany, Italy, and Spain
- Treatment decision tree for stage IV colorectal cancer: United Kingdom
- Treatment decision tree for stage IV colorectal cancer: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in colorectal cancer
- Top unmet needs in colorectal cancer: current and future attainment
- Expert insights: unmet need in colorectal cancer
- Drug pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for colorectal cancer
- Estimated market authorization dates of key emerging therapies for the treatment of colorectal cancer
- Key results from select clinical trials investigating fruquintinib for the treatment of colorectal cancer
- Analysis of the clinical development program for fruquintinib
- Expert insight: Fruquintinib
- Expectations for market authorization and sales opportunity of fruquintinib in colorectal cancer
- Key results from select clinical trials investigating Lenvima for the treatment of colorectal cancer
- Analysis of the clinical development program for Lenvima
- Key ongoing clinical trials of Lenvima in the treatment of colorectal cancer
- Expert insight: Lenvima
- Expectations for market authorization and sales opportunity of Lenvima in colorectal cancer
- Key results from select clinical trials investigating zanzalintinib for the treatment of colorectal cancer
- Analysis of the clinical development program for zanzalintinib
- Key ongoing clinical trials of zanzalintinib in the treatment of colorectal cancer
- Expectations for market authorization and sales opportunity of zanzalintinib in colorectal cancer
- Key results from select clinical trials investigating Krazati for the treatment of colorectal cancer
- Analysis of the clinical development program for Krazati
- Key ongoing clinical trials of Krazati in the treatment of colorectal cancer
- Expert insight: Krazati
- Expectations for the market authorization and sales opportunity of Krazati in colorectal cancer
- Lumakras / Lumykras
- Key results from select clinical trials investigating Lumakras / Lumykras for the treatment of colorectal cancer
- Analysis of the clinical development program for Lumakras / Lumykras
- Key ongoing clinical trials of Lumakras / Lumykras in the treatment of colorectal cancer
- Expert insight: Lumakras / Lumykras
- Expectations for market authorization and sales opportunity of Lumakras / Lumykras in colorectal cancer
- Key results from select clinical trials investigating Tecentriq for the treatment of colorectal cancer
- Analysis of the clinical development program for Tecentriq
- Key ongoing clinical trials of Tecentriq in the treatment of colorectal cancer
- Expert insight: Tecentriq
- Expectations for market authorization and sales opportunity of Tecentriq in colorectal cancer
- Key results from select clinical trials investigating the Favezelimab / Keytruda fixed-dose combination for the treatment of colorectal cancer
- Analysis of the clinical development program for Favezelimab / Keytruda fixed-dose combination
- Key ongoing clinical trials of Favezelimab / Keytruda fixed-dose combination in the treatment of colorectal cancer
- Expert insight: favezelimab / Keytruda fixed-dose combination (FDC)
- Expectations for the market authorization and sales opportunity for Favezelimab / Keytruda fixed-dose combination in colorectal cancer
- Analysis of the clinical development program for Opdualag
- Key ongoing clinical trials of Opdualag in the treatment of colorectal cancer
- Expert insight: Opdualag for the treatment of colorectal cancer
- Expectations for market authorization and sales opportunity for Opdualag in colorectal cancer
- Key results from select clinical trials investigating OncoVAX for the treatment of colorectal cancer
- Analysis of the clinical development program for OncoVAX
- Key ongoing clinical trials of OncoVAX in the treatment of colorectal cancer
- Expert insight: OncoVAX
- Expectations for market authorization and sales opportunity for OncoVAX in colorectal cancer
- Analysis of the clinical development program for Sym-004
- Key ongoing clinical trials of Sym-004 in the treatment of colorectal cancer
- Expert insight: Sym-004
- Expectations for market authorization and sales opportunity for Sym-004 in colorectal cancer
- Early-phase pipeline analysis
- Select compounds in early-phase development for colorectal cancer
- Key findings
- Access & reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in colorectal cancer: United States
- General reimbursement environment: United States
- Key market access considerations in colorectal cancer: EU5
- General reimbursement environment: EU5
- Key market access considerations in colorectal cancer: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Colorectal cancer bibliography
- Abbreviations
- Key findings
Laura Ramos Garcia, M.Sc., Ph.D., is an analyst on the Oncology team at Clarivate. During her training as a Ph.D., she gained in-depth knowledge in the field of cell death and inflammation. As a postdoctoral researcher, she worked on an emerging type of small molecule, PROTAC, that allows targeted protein degradation. She obtained her master of science degree in molecular medicine at Imperial College London and her doctorate in cancer biology at the Institute of Cancer Research (University of London).